MRI Agent Loaded Platelets for ARIA-H Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting amyloid-related imaging abnormalities with hemorrhage (ARIA-H) in Alzheimer's disease patients are limited by interpretation pitfalls, such as motion artifacts, susceptibility effects, and reader biases, which can lead to inaccurate detection of microhemorrhages.
Innovation Solution
The use of rehydrated freeze-dried platelet derivatives as biological carriers for MRI agents, which can be administered to patients with Alzheimer's disease to enhance the detection of ARIA-H by providing targeted delivery of imaging agents to brain bleeding sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional MRI methods are used to detect ARIA-H, then the detection process is straightforward, but the accuracy is compromised due to motion artifacts, susceptibility effects, and reader biases
Solution Approach 1:
The patent introduces platelet-derived microparticles as intermediary carriers that selectively accumulate at ARIA-H sites. These microparticles serve as a mediator between the MRI agent and the target lesion, concentrating the contrast agent precisely where needed to overcome the confounding effects of motion artifacts and susceptibility variations in conventional MRI.
Solution Approach 2:
The invention applies local quality by enabling selective accumulation of MRI agents at specific ARIA-H locations through platelet-derived microparticle targeting. Rather than uniform distribution, the microparticles concentrate the contrast agent locally at hemorrhage sites, enhancing signal intensity precisely where pathology exists and improving detection accuracy.
2Measurement precision
If platelet-derived microparticles are used as carriers, then targeted delivery to ARIA-H sites is achieved, but the complexity of preparation and administration increases
Solution Approach 1:
The platelet-derived microparticles exhibit self-service properties by autonomously accumulating at ARIA-H sites through their inherent interaction with the hemorrhagic environment. The microparticles self-target and self-concentrate at the lesion site without requiring external guidance systems or complex administration protocols, simplifying the overall system despite the biological complexity of the carriers.
Solution Approach 2:
The invention utilizes parameter changes in the physiological state of platelet-derived microparticles, specifically their activation and accumulation characteristics at hemorrhage sites. By leveraging changes in microparticle behavior (such as adhesion and accumulation) in response to the local hemorrhagic environment, the system achieves targeted delivery while maintaining relatively simple administration protocols.
3Measurement precision
If conventional MRI agents are administered systemically, then coverage is broad, but specificity for ARIA-H detection is reduced due to non-specific accumulation
Solution Approach 1:
The patent implements local quality by concentrating MRI agents specifically at ARIA-H sites through platelet-derived microparticle targeting. The microparticles ensure that the contrast agent is distributed non-uniformly, with high concentration at hemorrhage locations and minimal background signal, thereby achieving high specificity for ARIA-H detection.
Solution Approach 2:
The platelet-derived microparticles function as intermediary carriers that mediate the distribution of MRI agents. Rather than systemic distribution, the microparticles act as vectors that deliver the contrast agent selectively to ARIA-H sites, improving specificity while reducing non-specific background signal.
Data Source
AI summary
Provided herein are imaging agent-loaded cryopreserved platelets and platelet derivatives, such as MRI agent-loaded platelets and platelet derivatives, and methods of preparing and using the same. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent and a cell penetrating peptide. In some embodiments, methods of preparing MRI agent-loaded cryopreserved platelets or platelet derivatives in a dried powder, wherein the MRI agent-loaded cryopreserved platelets or the MRI agent-loaded platelet derivatives comprise an MRI agent complex covalently bonded to the surface of the cryopreserved platelets or the platelet derivatives.